These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15500391)

  • 1. The analgesic potential of clostridial neurotoxin derivatives.
    Foster KA
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1437-43. PubMed ID: 15500391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects.
    Pickett A
    BioDrugs; 2010 Jun; 24(3):173-82. PubMed ID: 20462283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics.
    Foster KA
    Drug Discov Today; 2005 Apr; 10(8):563-9. PubMed ID: 15837599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future directions of botulinum neurotoxins for targeting pain processing.
    Pellett S; Yaksh TL; Ramachandran R
    Toxins (Basel); 2015 Nov; 7(11):4519-63. PubMed ID: 26556371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.
    Tehran DA; Pirazzini M
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29748471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and molecular mechanisms involved in the analgesic effects of botulinum neurotoxin: A literature review.
    Hosseindoost S; Inanloo SH; Pestehei SK; Rahimi M; Yekta RA; Khajehnasiri A; Rad MA; Majedi H; Dehpour AR
    Drug Dev Res; 2024 Apr; 85(2):e22177. PubMed ID: 38528637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.
    Chaddock JA; Purkiss JR; Alexander FC; Doward S; Fooks SJ; Friis LM; Hall YH; Kirby ER; Leeds N; Moulsdale HJ; Dickenson A; Green GM; Rahman W; Suzuki R; Duggan MJ; Quinn CP; Shone CC; Foster KA
    Mov Disord; 2004 Mar; 19 Suppl 8():S42-7. PubMed ID: 15027053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic neurotoxins with enzymatic activities.
    Rossetto O; Montecucco C
    Handb Exp Pharmacol; 2008; (184):129-70. PubMed ID: 18064414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum neurotoxin].
    Poulain B
    Rev Neurol (Paris); 2010 Jan; 166(1):7-20. PubMed ID: 19846187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding of botulinum neurotoxins to different peripheral neurons.
    Rossetto O
    Toxicon; 2018 Jun; 147():27-31. PubMed ID: 29042309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
    Dolly JO; Wang J; Zurawski TH; Meng J
    FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum neurotoxins: mechanism of action.
    Tighe AP; Schiavo G
    Toxicon; 2013 Jun; 67():87-93. PubMed ID: 23201505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum neurotoxin: the ugly duckling.
    Koussoulakos S
    Eur Neurol; 2009; 61(6):331-42. PubMed ID: 19365125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of botulinum neurotoxin in pain management--an ongoing controversy.
    Ashkenazi A
    Curr Pain Headache Rep; 2009 Aug; 13(4):249-52. PubMed ID: 19586585
    [No Abstract]   [Full Text] [Related]  

  • 16. The analgesic effects of botulinum neurotoxin by modulating pain-related receptors; A literature review.
    Hosseindoost S; Askari Rad M; Inanloo SH; Rahimi M; Dehghan S; Orandi A; Dehpour AR; Majedi H
    Mol Pain; 2024; 20():17448069241275099. PubMed ID: 39093638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxins: mechanisms of action, antinociception and clinical applications.
    Wheeler A; Smith HS
    Toxicology; 2013 Apr; 306():124-46. PubMed ID: 23435179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins.
    Simpson LL
    J Pharmacol Exp Ther; 1988 Jun; 245(3):867-72. PubMed ID: 2455038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming the domain structure of botulinum neurotoxins into novel therapeutics.
    Chaddock J
    Curr Top Microbiol Immunol; 2013; 364():287-306. PubMed ID: 23239358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin for pain management: insights from animal models.
    Pavone F; Luvisetto S
    Toxins (Basel); 2010 Dec; 2(12):2890-913. PubMed ID: 22069581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.